Clinical specialities

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #PCR #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

New Options for Cell-Based Assay Automation

New Options for Cell-Based Assay Automation By Dr John Comley The findings of a recent survey on cell-based assay automation revealed that no single factor stands out as the predominant reason productivity is limited in current cell-based automation. However, improving the quality of assay results and enhancing throughput were seen… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Genomics #Imaging #Lead discovery #Metabolomics #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA

The future of the CRO industry

The future of the CRO industry By Gilbert Godin The pressures on Pharma/Biotech to control R&D costs while improving the yield of new, approvable drugs indicate an even greater reliance on outsourcing. So what will the next five years bring for the CRO industry? Five years ago, as we approached… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

Ion Channels – New opportunities for an established therapeutic target class

Ion Channels - New opportunities for an established therapeutic target class By Dr Andrew Southan, Iain F. James and David Cronk There is an increasing recognition within the pharmaceutical industry of the immense potential for ion channels as a drug target class. Advances in the understanding of the human genome,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Pharmokinetics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Nanotechnology approaches to solving the problems of poorly water-soluble drugs

Nanotechnology approaches to solving the problems of poorly water-soluble drugs By Dr Roghieh Saffie-Siebert, Dr Jill Ogden and Dr Mark Parry-Billings Traditionally, almost half of new molecular entities identified by pharmaceutical industry screening programmes have failed to be developed because of poor water-solubility, which makes their formulation difficult or even… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Enabling technologies #High throughput screening #Immunology #Lead discovery #Lead optimisation #Molecular medicine #Preclinical #RNA #Screening #Stem cells

Creating a productive R&D culture

Creating a productive R&D culture By Janet White Increasing R&D productivity is the current mantra of pharmaceutical industry executives. The promise of new technologies and process improvements has been extensively discussed. However, fundamental culture change within research organisations remains the final unexplored frontier to increased productivity. This article introduces the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Lead discovery #PCR #Regulatory #RNA #Target validation

Ontologies – Semantic networks of pharmaceutical knowledge

Ontologies - Semantic networks of pharmaceutical knowledge By Dr Stephen P. Gardner In the current climate making information more transparent to internal R&D staff and to external audiences such as regulators and consumers is crucial to business effectiveness. A new generation of semantic technologies capable of generating a consistent view… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Immunology #Lead discovery #Organic chemistry #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Cryo Electron Microscopy and Electron Tomography

Cryo Electron Microscopy and Electron Tomography By Dr Jack Elands and Dr Ulf Skoglund Cryo electron microscopy and electron tomography will play a crucial role in the future of drug development. The completion of the human genome project has focused tremendous interest in determining the structure and function of the… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Business #Cell therapy #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Pharmokinetics #Preclinical #Regulatory #Screening #Toxicology

Exposure response modelling a safe and profitable way to speed drugs to market

Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in silico technique, in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #RNA #Screening #Target validation

Compound Management – In pursuit of sample integrity

Compound Management - In pursuit of sample integrity By Dr John Comley In December 2004 HTStec published its report on Compound Management Trends. This market report summarises the results of a global benchmarking study on pharmaceutical compound management (CM), documenting current practices, issues and future trends in CM, with a… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Overview of biomarkers in disease, drug discovery and development

Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #Immunology #Molecular medicine #Oncology #Patent Law #RNA #Screening #Stem cells

Patent Pools as a Solution to the licensing problems of diagnostic genetics – United States and European perspectives

Patent Pools as a Solution to the licensing problems of diagnostic genetics - United States and European perspectives By Dr Jorge A. Goldstein, Dr Ted J. Ebersole, Marvin C. Guthrie, Annette A. Hirschfeld and Bart J. van den Broek Advances in diagnostic genetic testing have resulted in the ability to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Lead discovery #Molecular medicine #Oncology #Organic chemistry #Regulatory #RNA #Sequencing #Stem cells #Therapeutics #Toxicology

COX-2 Inhibitor Toxicity – Warning shot over pharma’s bow

COX-2 Inhibitor Toxicity - Warning shot over pharma's bow By Dr Mark Schena and Dr William Greene Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable… Read More

#Archive

#Analysis #Animal models #Assay development & optimisation #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #Imaging #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #Target validation #Toxicology

The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines

The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines By Professor Jan Tornell The pharmaceutical industry is faced with the challenge to deliver truly novel medicines to a market under financial pressure when pharmaceutical R&D becomes increasingly difficult and complex. This review will mainly focus on… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Biomarkers #Business #Clinical specialities #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmacogenomics #Pharmacology #Preclinical #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Experimental Medicine – Developing biomarkers in early discovery to bridge preclinical and clinical development

Experimental Medicine - Developing biomarkers in early discovery to bridge preclinical and clinical development By Dr Robert Dix In today's pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing), resulting in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Clinical Proteomics: Opportunities in drug discovery and development

By Dr Ashok R Dongre, Dr Douglas Robinson, Dr Mark E Curran and Dr Nicholas C Dracopoli Molecular profiling is becoming increasingly important as a tool for the discovery and implementation of novel biomarkers for use in drug development. Modern profiling methods permit comprehensive analysis of biological systems that allow,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #RNA #Screening #Sequencing #Toxicology

Leveraging the ion channel platform for lead generation in atrial fibrillation

Leveraging the ion channel platform for lead generation in atrial fibrillation By Professor Andreas Busch Competition in the pharmaceutical industry requires a reduction in research and development project cycle times and, accordingly, an increase in productivity and efficiency. Pharmaceutical companies also are faced with the challenge of translating massive amounts… Read More

#Archive